A DIGITAL PATHFINDER FOR HISTORIC SITES

The Digital Pathfinder for Historic Sites Project will develop a new model for tours at historic sites. It uses a hand-held GPS personal data assistant programmed with open source software to provide interactive digital maps, navigation, rich media, and other information about the site and its environment. The platform is cost-effective and flexible, allowing each visitor to select the path, duration, and depth of their tour. The start-up funds will focus on the Staatsburgh Estate, the largest of two Beaux Arts properties among the Great Estates of the Hudson River Valley. The mansion and grounds exemplify the elegant estates built by America's financial and industrial leaders during the Gilded Age, known as the American Renaissance, which lasted from 1876 to 1917. This period was marked by America's rapid economic growth and emergence as a world power. The template being developed will readily adapt to other great estates or any historic site or museum that interprets its grounds

Prospectus, May 6, 1974

KAREN COLEMAN ELECTED NEW STU-GO PRES; Gallup Explains Effect Of Polls; Parkland Debate Team Ends Year At Nationals; All Races Close Despite Poor Voter Turnout; Enthusiam Abounds At IOC Spring Carnival; IE Team Winds-Up Season With Good National Showing; Parkland College Foundation Officers Selected At Meeting; Cruisin\u27 \u2774; Letter To The Editor; The Short Circuit; Let\u27s Go To The Bars; IVC New Service Officer, Menaugh; Vet\u27s Corner; Monday\u27s Coach; Cobras Win One, Lose Three In Double-Header; Parkland Athlete Randy Williams Looks Over Schools; I/M Tryouts Now For And Tennis Track, Golf; Amana Commune, A Lifestyle From A Dream; Pulitzer Prize Poet To Appear At Parkland; Library Hours During Exam Week; A Column By and For Women; National Women\u27s Music Festival; Crosswords; Student Raffle; President\u27s Report; Registration Info For Fall, 1974 Available To Students Now; Happy Birthday; Classified Ads; Parkland Players To Present Play; Recycle Paper; Wainwright Captures Audience With Real Life Situations; American Odyssey; Parkland Events; Final Exam Schedule - Spring Quarter, 1973-1974; Sangamon State Representative; Krannert Art Schedulehttps://spark.parkland.edu/prospectus_1974/1013/thumbnail.jp

Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits

Mammographic screening before age 50 years is less effective than at older ages and the associated radiation risks are higher. We estimated how many breast cancer deaths could be caused and how many could be prevented by a decade of annual two-view mammographic screening starting at ages 20, 30 and 40 years, respectively, in the UK; for all women, and for women with first-degree relatives affected with breast cancer. We extrapolated from a radiation risk model to estimate the number of radiation-induced breast cancer deaths, and used results from randomised trials, which suggest a reduction in breast cancer mortality of 10–20% in women invited to screening before age 50 years, to estimate the number of deaths that could be prevented. The net change in breast cancer deaths was defined as the number of radiation-induced deaths minus the number of prevented deaths. For all women, assuming a reduction in mortality from screening of 20%, a decade of annual screening was estimated to induce more deaths than it prevents if started at age 20 years and at age 30 years (net increase=0.86 and 0.37 breast cancer deaths, respectively, per 1000 women screened). The corresponding estimate for screening starting at age 40 years was a net decrease of 0.46 deaths/1000 women screened and a zero net change assuming a 10% mortality reduction. Results for women with first-degree relatives with breast cancer were generally in the same direction but, because their background incidence rates are higher, the net increases or decreases were greater. In conclusion, our estimates suggest that a decade of annual two-view mammographic screening before age 40 years would result in a net increase in breast cancer deaths, and that starting at age 40 years could result in a material net decrease only if breast cancer mortality is reduced by about 20% or more in women screened. Although these calculations were based on a number of uncertain parameters, in general, the conclusions were not altered when these parameters were varied within a feasible range

The TOPGAME-study: effectiveness of extracorporeal shockwave therapy in jumping athletes with patellar tendinopathy. Design of a randomised controlled trial

BACKGROUND: Patellar tendinopathy is a major problem for many athletes, especially those involved in jumping activities. Despite its frequency and negative impact on athletic careers, no evidence-based guidelines for management of this overuse injury exist. Since functional outcomes of conservative and surgical treatments remain suboptimal, new diagnostic and therapeutic strategies have to be developed and evaluated. Extracorporeal shockwave therapy (ESWT) appears to be a promising treatment in patients with chronic patellar tendinopathy. ESWT is most often applied after the known conservative treatments have failed. However, its effectiveness as primary therapy has not been studied in athletes who keep playing sports despite having patellar tendon pain. The aim of this study is to determine the effectiveness of ESWT in athletes with patellar tendinopathy who are still in training and competition. METHODS/DESIGN: The TOPGAME-study (Tendinopathy of Patella Groningen Amsterdam Maastricht ESWT) is a multicentre two-armed randomised controlled trial with blinded participants and outcome assessors, in which the effectiveness of patient-guided focussed ESWT treatment (compared to placebo ESWT) on pain reduction and recovery of function in athletes with patellar tendinopathy will be investigated. Participants are volleyball, handball and basketball players with symptoms of patellar tendinopathy for a minimum of 3 to a maximum duration of 12 months who are still able to train and compete. The intervention group receives three patient-guided focussed medium-energy density ESWT treatments without local anaesthesia at a weekly interval in the first half of the competition. The control group receives placebo treatment. The follow-up measurements take place 1, 12 and 22 weeks after the final ESWT or placebo treatment, when athletes are still in competition. Primary outcome measure is the VISA-P (Victorian Institute of Sport Assessment - patella) score. Data with regard to pain during function tests (jump tests and single-leg decline squat) and ultrasound characteristics are also collected. During the follow-up period participants also register pain, symptoms, sports participation, side effects of treatment and additional medical consumption in an internet-based diary. DISCUSSION: The TOPGAME-study is the first RCT to study the effectiveness of patient-guided ESWT in athletes with patellar tendinopathy who are still in training and competition. TRIAL REGISTRATION: Trial registration number NTR1408